<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794974</url>
  </required_header>
  <id_info>
    <org_study_id>A 2016-0027</org_study_id>
    <nct_id>NCT02794974</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Intermediate Cervical Plexus Block</brief_title>
  <official_title>Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Endarterectomies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helios Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helios Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators test with the present study design, whether an ultrasound-guided blockade
      of the cervical plexus in combination with an additional application of local anesthetic to
      the superficial cervical ansa (facial nerve: cervical branch) leads to an improved quality of
      anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The innervation of the neck area is complex and includes cranial nerve (innervation of the
      vessel wall (IX,X) and of the neck muscles (VII,XI)), as well as the cervical plexus and
      brachial plexus. This is a major cause of insufficient anesthesia quality during carotid
      endarterectomies.

      The investigators test with the present prospective study design, whether an
      ultrasound-guided blockade of the cervical plexus in combination with an additional
      application of local anesthetic to the superficial cervical ansa (facial nerve: cervical
      branch) leads to an improved quality of anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Anesthetic Supplementation (Frequency)</measure>
    <time_frame>intraoperatively</time_frame>
    <description>number of participants who need supplementation of prilocaine 1% by the surgeon (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Anesthetic Supplementation (Volume)</measure>
    <time_frame>intraoperatively</time_frame>
    <description>volume of prilocaine 1% supplemented by the surgeon (ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hoarseness</measure>
    <time_frame>intraoperatively</time_frame>
    <description>number of participants who experienced side effects: hoarseness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough</measure>
    <time_frame>intraoperatively</time_frame>
    <description>number of participants who experienced side effects: cough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysphagia</measure>
    <time_frame>intraoperatively</time_frame>
    <description>number of participants who experienced side effects: dysphagia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Internal Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>with perivascular block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without perivascular block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cervical plexus block</intervention_name>
    <description>ultrasound-guided application of 20ml ropivacaine 0.75%</description>
    <arm_group_label>with perivascular block</arm_group_label>
    <arm_group_label>without perivascular block</arm_group_label>
    <other_name>cervical plexus anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>facial nerve block</intervention_name>
    <description>ultrasound-guided application of 5ml prilocaine 1%</description>
    <arm_group_label>with perivascular block</arm_group_label>
    <arm_group_label>without perivascular block</arm_group_label>
    <other_name>facial nerve anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>perivascular block</intervention_name>
    <description>ultrasound-guided application of 5ml prilocaine 1%</description>
    <arm_group_label>with perivascular block</arm_group_label>
    <other_name>perivascular infiltration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  internal carotid stenosis: open surgical revascularization

          -  age over 18 years

          -  written informed consent

        Exclusion Criteria:

          -  allergy (local anesthetics)

          -  pregnancy

          -  participation in other studies

          -  drug addiction

          -  non-cooperative patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Seidel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Medical Center Schwerin, Department of Anesthesiology and Intensive care,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helios Medical Center Schwerin, Department of Anaesthesiology and Intensive Care</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <results_first_submitted>November 20, 2017</results_first_submitted>
  <results_first_submitted_qc>November 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2018</results_first_posted>
  <last_update_submitted>November 28, 2018</last_update_submitted>
  <last_update_submitted_qc>November 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helios Research Center</investigator_affiliation>
    <investigator_full_name>Dr.med.Ronald Seidel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02794974/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02794974/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patients were recruited as part of the preoperative information discussion. All patients received an intermediate cervical plexus block and a facial nerve block (cervical branch, superficial cervical ansa). The decision on an additional perivascular infiltration was made by an experienced physician on the basis of sonoanatomic properties.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervical Plexus and Facial Nerve Block</title>
          <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%</description>
        </group>
        <group group_id="P2">
          <title>Cervical Plexus, Perivascular and Facial Nerve Block</title>
          <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%) 3. perivascular local anesthetic infiltration (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%
perivascular block: ultrasound-guided application of 5ml prilocaine 1%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervical Plexus, Perivascular and Facial Nerve Block</title>
          <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%) 3. perivascular local anesthetic infiltration (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%
perivascular block: ultrasound-guided application of 5ml prilocaine 1%</description>
        </group>
        <group group_id="B2">
          <title>Cervical Plexus and Facial Nerve Block</title>
          <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="9"/>
                    <measurement group_id="B2" value="71" spread="10"/>
                    <measurement group_id="B3" value="69" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Anesthetic Supplementation (Frequency)</title>
        <description>number of participants who need supplementation of prilocaine 1% by the surgeon (%)</description>
        <time_frame>intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervical Plexus and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
          <group group_id="O2">
            <title>Cervical Plexus, Perivascular and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%) 3. perivascular local anesthetic infiltration (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%
perivascular block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
        </group_list>
        <measure>
          <title>Local Anesthetic Supplementation (Frequency)</title>
          <description>number of participants who need supplementation of prilocaine 1% by the surgeon (%)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.236</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Local Anesthetic Supplementation (Volume)</title>
        <description>volume of prilocaine 1% supplemented by the surgeon (ml)</description>
        <time_frame>intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervical Plexus and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
          <group group_id="O2">
            <title>Cervical Plexus, Perivascular and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%) 3. perivascular local anesthetic infiltration (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%
perivascular block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
        </group_list>
        <measure>
          <title>Local Anesthetic Supplementation (Volume)</title>
          <description>volume of prilocaine 1% supplemented by the surgeon (ml)</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.1"/>
                    <measurement group_id="O2" value="1.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hoarseness</title>
        <description>number of participants who experienced side effects: hoarseness</description>
        <time_frame>intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervical Plexus and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
          <group group_id="O2">
            <title>Cervical Plexus, Perivascular and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%) 3. perivascular local anesthetic infiltration (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%
perivascular block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
        </group_list>
        <measure>
          <title>Hoarseness</title>
          <description>number of participants who experienced side effects: hoarseness</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.209</p_value>
            <method>Odds Ratio</method>
            <param_type>Odds Ratio</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>32.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cough</title>
        <description>number of participants who experienced side effects: cough</description>
        <time_frame>intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervical Plexus and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
          <group group_id="O2">
            <title>Cervical Plexus, Perivascular and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%) 3. perivascular local anesthetic infiltration (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%
perivascular block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
        </group_list>
        <measure>
          <title>Cough</title>
          <description>number of participants who experienced side effects: cough</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Odds Ratio</method>
            <param_type>Odds Ratio</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>12.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dysphagia</title>
        <description>number of participants who experienced side effects: dysphagia</description>
        <time_frame>intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervical Plexus and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
          <group group_id="O2">
            <title>Cervical Plexus, Perivascular and Facial Nerve Block</title>
            <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%) 3. perivascular local anesthetic infiltration (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%
perivascular block: ultrasound-guided application of 5ml prilocaine 1%</description>
          </group>
        </group_list>
        <measure>
          <title>Dysphagia</title>
          <description>number of participants who experienced side effects: dysphagia</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.695</p_value>
            <method>Odds Ratio</method>
            <param_type>Odds Ratio</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>9.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Without Perivascular Block</title>
          <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%</description>
        </group>
        <group group_id="E2">
          <title>With Perivascular Block</title>
          <description>1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)
cervical plexus block: ultrasound-guided application of 20ml ropivacaine 0.75%
facial nerve block: ultrasound-guided application of 5ml prilocaine 1%
perivascular block: ultrasound-guided application of 5ml prilocaine 1%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Seidel</name_or_title>
      <organization>HELIOS Medical Center Schwerin, Germany</organization>
      <phone>+49 385 5204251</phone>
      <email>ronald.seidel@helios-kliniken.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

